North Wales - November 10, 2009
Quay Pharmaceuticals is investing £2.7million in a new headquarters and manufacturing facility in North Wales where, with support from the Welsh Assembly Government, it will create 54 new high quality jobs. Operations at the new site will include early stage research & development and clinical trials manufacturing for the global pharmaceutical and biotechnology industries.
Quay Pharma is a welcome addition to the healthcare and bioscience sector in Wales which employs some 15,000 people and is worth around £1.3billion annually to the Welsh economy. Support was provided through the Single Investment Fund to facilitate the company’s expansion programme, said Ieuan Wyn Jones, Minister for the Economy and Transport.
“Quay Pharma will be creating a range of high quality jobs over the next few years providing excellent employment opportunities for Welsh graduates,” said Wyn Jones.
The range of support offered by the Assembly Government to small and medium sized businesses had made Wales an attractive proposition for Quay Pharma’s expansion, Chief Executive Officer Mike Rubinstein said.
“The support from the Assembly Government is great for a small company and of particular help in the current economic climate. Not only does it provide advice and access to knowledge but also provides businesses with a high level of promotional and marketing support at overseas events," Rubenstein said.
The company is currently fitting out laboratories and offices with the aim of opening in January. The manufacturing operation is due to relocate during the first quarter of next year.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.